D L Veenstra

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. ncbi request reprint Efficacy of antiseptic-impregnated central venous catheters in preventing catheter-related bloodstream infection: a meta-analysis
    D L Veenstra
    Department of Pharmacy, University of Washington, Seattle, USA
    JAMA 281:261-7. 1999
  2. ncbi request reprint Systematic review of comparative effectiveness data for oncology orphan drugs
    Mindy M Cheng
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA 98195 7630, USA
    Am J Manag Care 18:47-62. 2012
  3. doi request reprint HBeAg-negative chronic hepatitis B: cost-effectiveness of peginterferon alfa-2a compared to lamivudine in Taiwan
    David L Veenstra
    University of Washington, Seattle, WA, USA
    Value Health 11:131-8. 2008
  4. ncbi request reprint Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient, and economic outcomes
    David L Veenstra
    Institute for Public Health Genetics, Department of Pharmacy, University of Washington, Seattle, Washington 98195, USA
    Genet Med 9:695-704. 2007
  5. ncbi request reprint Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B
    David L Veenstra
    Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, Washington 98195, USA
    Pharmacoeconomics 25:963-77. 2007
  6. ncbi request reprint Cost-effectiveness of peginterferon alpha-2a compared with lamivudine treatment in patients with HBe-antigen-positive chronic hepatitis B in the United Kingdom
    David L Veenstra
    University of Washington, Seattle, Washington 98195, USA
    Eur J Gastroenterol Hepatol 19:631-8. 2007
  7. doi request reprint Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis
    D L Veenstra
    Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA 98195, USA
    Aliment Pharmacol Ther 27:1240-52. 2008
  8. ncbi request reprint A guideline for the use of pharmacoeconomic models of diabetes treatment in the US managed-care environment
    David L Veenstra
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, Washington, USA
    Pharmacoeconomics 20:21-30. 2002
  9. pmc A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice
    David L Veenstra
    Department of Pharmacy, University of Washington, Seattle, Washington 98195, USA
    Genet Med 12:686-93. 2010
  10. pmc Assessing the cost-effectiveness of pharmacogenomics
    D L Veenstra
    Pharmaceutical Outcomes Research and Policy Program and Public Health Genetics Program, University of Washington, Department of Pharmacy, Seattle, WA 98195, USA
    AAPS PharmSci 2:E29. 2000

Detail Information

Publications65

  1. ncbi request reprint Efficacy of antiseptic-impregnated central venous catheters in preventing catheter-related bloodstream infection: a meta-analysis
    D L Veenstra
    Department of Pharmacy, University of Washington, Seattle, USA
    JAMA 281:261-7. 1999
    ..However, there remains some uncertainty regarding the efficacy of these catheters because of conflicting reports in the literature...
  2. ncbi request reprint Systematic review of comparative effectiveness data for oncology orphan drugs
    Mindy M Cheng
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA 98195 7630, USA
    Am J Manag Care 18:47-62. 2012
    ..To systematically assess clinical and economic evidence for oncology orphan drugs marketed in the United States and to highlight the challenges and opportunities for evidence development within this pharmaceutical category...
  3. doi request reprint HBeAg-negative chronic hepatitis B: cost-effectiveness of peginterferon alfa-2a compared to lamivudine in Taiwan
    David L Veenstra
    University of Washington, Seattle, WA, USA
    Value Health 11:131-8. 2008
    ..Our objective is to evaluate the incremental cost-effectiveness of 48 weeks of peginterferon alfa-2a compared to 48 weeks of lamivudine, from the perspective of the Taiwan Bureau of National Health Insurance...
  4. ncbi request reprint Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient, and economic outcomes
    David L Veenstra
    Institute for Public Health Genetics, Department of Pharmacy, University of Washington, Seattle, Washington 98195, USA
    Genet Med 9:695-704. 2007
    ..Although the A1555G variant is very rare, it seems to confer a high risk of severe hearing loss in patients exposed to aminoglycosides...
  5. ncbi request reprint Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B
    David L Veenstra
    Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, Washington 98195, USA
    Pharmacoeconomics 25:963-77. 2007
    ..Previous economic analyses have been limited by the lack of comparative clinical data for entecavir and lamivudine beyond 1-year duration and for salvage therapy...
  6. ncbi request reprint Cost-effectiveness of peginterferon alpha-2a compared with lamivudine treatment in patients with HBe-antigen-positive chronic hepatitis B in the United Kingdom
    David L Veenstra
    University of Washington, Seattle, Washington 98195, USA
    Eur J Gastroenterol Hepatol 19:631-8. 2007
    ..We assessed the clinical outcomes and costs, from the perspective of the UK National Health Service, of 48 weeks of peginterferon alpha-2a (40 kDa) vs. 4 years of lamivudine...
  7. doi request reprint Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis
    D L Veenstra
    Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA 98195, USA
    Aliment Pharmacol Ther 27:1240-52. 2008
    ..Several anti-viral treatments are now available for HBeAg-negative chronic hepatitis B (CHB), but the clinical and economic outcomes of potential treatment strategies and durations are unclear...
  8. ncbi request reprint A guideline for the use of pharmacoeconomic models of diabetes treatment in the US managed-care environment
    David L Veenstra
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, Washington, USA
    Pharmacoeconomics 20:21-30. 2002
    ....
  9. pmc A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice
    David L Veenstra
    Department of Pharmacy, University of Washington, Seattle, Washington 98195, USA
    Genet Med 12:686-93. 2010
    ..To address these issues, this study presents a risk-benefit framework for assessing the health-related utility of genomic tests...
  10. pmc Assessing the cost-effectiveness of pharmacogenomics
    D L Veenstra
    Pharmaceutical Outcomes Research and Policy Program and Public Health Genetics Program, University of Washington, Department of Pharmacy, Seattle, WA 98195, USA
    AAPS PharmSci 2:E29. 2000
    ....
  11. ncbi request reprint Cost-effectiveness of antiseptic-impregnated central venous catheters for the prevention of catheter-related bloodstream infection
    D L Veenstra
    Pharmaceutical Outcomes Research and Policy Program and Department of Pharmacy, University of Washington, Seattle 98195 7630, USA
    JAMA 282:554-60. 1999
    ....
  12. ncbi request reprint Management strategies for ribavirin-induced hemolytic anemia in the treatment of hepatitis C: clinical and economic implications
    E B Devine
    University of Washington, Department of Pharmacy, Box 357630, Seattle, WA 98195 7630, USA
    Value Health 4:376-84. 2001
    ..The objective of this study was to evaluate the direct health-care costs and management of RIHA during treatment of CHC in a clinical trial setting...
  13. ncbi request reprint A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B
    D Eldon Spackman
    Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, Washington, USA
    Pharmacoeconomics 26:937-49. 2008
    ..The goal of this analysis was to compare the cost effectiveness of adefovir, entecavir, lamivudine, pegylated interferon and telbivudine...
  14. ncbi request reprint A pharmacoeconomic analysis of pegaspargase versus native Escherichia coli L-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: the Children's Cancer Group study (CCG-1962)
    Helen A Kurre
    Clinical Services Administration, Children s Hospital and Regional Medical Center, Seattle, Washington, USA
    J Pediatr Hematol Oncol 24:175-81. 2002
    ..a newer chemotherapeutic agent used for treating acute lymphoblastic leukemia, with native Escherichia coli L-asparaginase in induction, delayed intensification 1 and delayed intensification 2...
  15. ncbi request reprint The cost-effectiveness of interleukin-1 genetic testing for periodontal disease
    Mitchell K Higashi
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle 98195 7630, USA
    J Periodontol 73:1474-84. 2002
    ..The objective of this study was to determine the clinical scenario required to produce cost-effective results with the use of IL-1 testing to identify high-risk patients...
  16. ncbi request reprint Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds
    Stephen J Rulyak
    University of Washington, Division of Gastroenterology, Department of Pharmacy, Seattle, Washington, USA
    Gastrointest Endosc 57:23-9. 2003
    ..Endoscopic screening of families predisposed to pancreatic cancer is increasingly used, but the cost-effectiveness of screening is unknown...
  17. ncbi request reprint Gene expression profiling and breast cancer care: what are the potential benefits and policy implications?
    Nina Oestreicher
    University of Washington, Seattle, Washington, USA
    Genet Med 7:380-9. 2005
    ..However, the outcomes associated with gene expression profiling are not clear, and guidelines for the appropriate use of genomic technologies have not been established...
  18. ncbi request reprint Economic evaluation of systemic treatments for cytomegalovirus retinitis in patients with AIDS
    T A Lee
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle 98195, USA
    Pharmacoeconomics 19:535-50. 2001
    ..To determine the cost of using systemic therapy to treat newly diagnosed cytomegalovirus (CMV) retinitis in persons with AIDS...
  19. ncbi request reprint Pharmacoeconomic evaluations in the treatment of non-small cell lung cancer
    Josh J Carlson
    School of Public Health and Community Medicine, Institute for Public Health Genetics, University of Washington, Seattle, Washington, USA
    Drugs 68:1105-13. 2008
    ..Given the absence of studies on newer therapeutics and the lack of cost-utility studies, additional studies are warranted...
  20. pmc Modeling the cost and outcomes of pharmacist-prescribed emergency contraception
    K D Marciante
    Department of Pharmacy, University of Washington, Seattle, 98195, USA
    Am J Public Health 91:1443-5. 2001
    ..This study investigated the effect on the risk and cost of unintended pregnancies of emergency contraceptive pills obtained directly from a pharmacist...
  21. ncbi request reprint Cost-effectiveness of peginterferon alpha-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan
    Sean D Sullivan
    University of Washington, Seattle, Washington 98195, USA
    J Gastroenterol Hepatol 22:1494-9. 2007
    ....
  22. ncbi request reprint Screening for the alpha-adducin Gly460Trp variant in hypertensive patients: a cost-effectiveness analysis
    Lisa M Meckley
    University of Washington, Seattle WA 98195 7630, USA
    Pharmacogenet Genomics 16:139-47. 2006
    ..The objective of this study was to evaluate the potential cost effectiveness of screening for the alpha-adducin Gly460Trp variant among hypertensive patients...
  23. ncbi request reprint A review of public policy issues in promoting the development and commercialization of pharmacogenomic applications: challenges and implications
    Louis P Garrison
    Department of Pharmacy, University of Washington, Seattle, Washington 98195, USA
    Drug Metab Rev 40:377-401. 2008
    ..How well the numerous important stakeholders - both private and public - address these issues will be critical for pharmacogenomics to deliver on its promise...
  24. doi request reprint The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer
    Josh J Carlson
    School of Pharmacy, University of Washington, Seattle, WA 98195, USA
    Value Health 12:20-7. 2009
    ..The objective of this study was to evaluate the potential cost-utility of implementing epidermal growth factor receptor (EGFR) testing before initiating second-line therapy for advanced refractory non-small-cell lung cancer (NSCLC)...
  25. doi request reprint Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis
    Josh John Carlson
    Pharmaceutical Outcomes Research and Policy Program, School of Pharmacy, University of Washington, Seattle, WA 98195, USA
    J Cancer Res Clin Oncol 135:1483-93. 2009
    ....
  26. doi request reprint A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing
    Lisa M Meckley
    Department of Pharmacy, University of Washington, Seattle, Washington 98195, USA
    Pharmacoeconomics 28:61-74. 2010
    ..Payers will be facing increasing demand for coverage decisions regarding this technology, but the potential clinical and economic impacts of testing are not clear...
  27. doi request reprint Preference values associated with stage III colon cancer and adjuvant chemotherapy
    Jennie H Best
    University of Washington, Seattle, WA, USA
    Qual Life Res 19:391-400. 2010
    ..To elicit preference values for health states associated with Stage III colon cancer (CRC) and to explore the effect of neuropathy associated with current adjuvant treatment...
  28. doi request reprint Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers
    Josh J Carlson
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, 1959 NE Pacific Street, Seattle, WA 98195 7630, United States
    Health Policy 96:179-90. 2010
    ..To identify, categorize and examine performance-based health outcomes reimbursement schemes for medical technology...
  29. doi request reprint The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer
    Louis P Garrison
    Department of Pharmacy, University of Washington, Health Sciences Building, Seattle, WA 98195 7630, USA
    Value Health 12:1118-23. 2009
    ....
  30. ncbi request reprint Cost comparison of surgery vs organ preservation for laryngeal cancer
    Greg E Davis
    Department of Otolaryngology Head and Neck Surgery, Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA 98195, USA
    Arch Otolaryngol Head Neck Surg 131:21-6. 2005
    ..To perform a cost minimization analysis of total laryngectomy with postoperative radiotherapy vs induction chemotherapy with subsequent radiotherapy in patients with advanced (stage III or IV) squamous cell carcinoma of the larynx...
  31. ncbi request reprint Managed care in the genomics era: assessing the cost effectiveness of genetic tests
    Mitchell K Higashi
    Pharmaceutical Outcomes Research and Policy Program, Institute for Public Health Genetics, University of Washington, Seattle, Wash 98195, USA
    Am J Manag Care 9:493-500. 2003
    ..Managed care organizations will face reimbursement decisions for genetic tests on a growing scale, and they should have a framework in place to evaluate the clinical and economic outcomes of this new class of diagnostics...
  32. ncbi request reprint A Bayesian approach to aid in formulary decision making: incorporating institution-specific cost-effectiveness data with clinical trial results
    Shelby D Reed
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, USA
    Med Decis Making 23:252-64. 2003
    ..Among patients undergoing coronary stenting, the cost-effectiveness ratio of the addition of abciximab was at or below the $50,000 per life year saved threshold in 66.0% of the simulations...
  33. ncbi request reprint Comparative economic analyses of minimally invasive direct coronary artery bypass surgery
    Darryl T Gray
    Department of Community Research and Community Education, The Hope Heart Institute, Seattle, Wash, USA
    J Thorac Cardiovasc Surg 125:618-24. 2003
    ....
  34. ncbi request reprint Use of maximal sterile barriers during central venous catheter insertion: clinical and economic outcomes
    Kent K Hu
    Northwest Health Services Research and Development Program, Veterans Affairs Puget Sound Health Care System, University of Washington, Seattle 98108, USA
    Clin Infect Dis 39:1441-5. 2004
    ..Use of MSBs when placing CVCs may reduce the risk of infections but is more cumbersome, time-consuming, and expensive than other techniques...
  35. ncbi request reprint Health state preference assessment in diabetic peripheral neuropathy
    Sean D Sullivan
    Department of Pharmacy, University of Washington, Seattle, Washington 98195 7630, USA
    Pharmacoeconomics 20:1079-89. 2002
    ..To assess patient preferences for health states associated with diabetic peripheral neuropathy (DPN)...
  36. doi request reprint A risk-benefit assessment of prasugrel, clopidogrel, and genotype-guided therapy in patients undergoing percutaneous coronary intervention
    G F Guzauskas
    Institute for Public Health Genetics, University of Washington, Seattle, WA, USA
    Clin Pharmacol Ther 91:829-37. 2012
    ..Use of patient-specific factors such as CYP2C19 genotype offers promise for developing a personalized medicine approach to antiplatelet treatment regimens...
  37. ncbi request reprint The use of meta-analysis in cost-effectiveness analysis. Issues and recommendations
    S Saint
    Department of Medicine, University of Washington, Seattle, USA
    Pharmacoeconomics 15:1-8. 1999
    ..We conclude by providing guidance on the appropriate use of summary measures derived from meta-analyses for cost-effectiveness studies...
  38. ncbi request reprint Which antimicrobial impregnated central venous catheter should we use? Modeling the costs and outcomes of antimicrobial catheter use
    Kristin D Marciante
    Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle WA 98195, USA
    Am J Infect Control 31:1-8. 2003
    ..It remains unclear whether minocycline/rifampin catheters are cost-effective for all high-risk patients or only those requiring longer-term catheterization...
  39. pmc An evaluation of the potential cost-effectiveness of non-invasive testing strategies in the diagnosis of significant liver fibrosis
    Josh J Carlson
    Institute for Public Health Genetics, School of Public Health and Community Medicine, University of Washington, Washington 98195, USA
    J Gastroenterol Hepatol 24:786-91. 2009
    ..To assess the clinical and economic outcomes of non-invasive testing strategies in the diagnosis of significant liver fibrosis (Metavir score >or= 2) compared with liver biopsy...
  40. ncbi request reprint The timing of elective colectomy in diverticulitis: a decision analysis
    Leon Salem
    Department of Surgery, University of Washington, Seattle, WA 98195 6410, USA
    J Am Coll Surg 199:904-12. 2004
    ..We used decision and cost analysis to simulate the clinical and economic outcomes after recovery from an episode of nonsurgically treated diverticulitis to determine the preferable management strategy...
  41. doi request reprint Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC)
    Josh J Carlson
    Institute for Public Health Genetics, School of Public Health and Community Medicine, University of Washington, Seattle, United States
    Lung Cancer 61:405-15. 2008
    ..Various drug therapies are available for treatment of refractory stage IIIB/IV non-small cell lung cancer (NSCLC), but their comparative economic value is unclear...
  42. doi request reprint Can modeling of health outcomes facilitate regulatory decision making? The benefit-risk tradeoff for rosiglitazone in 1999 vs. 2007
    J T Cross
    Pharmaceutical Outcomes Research and Policy Program, School of Pharmacy, University of Washington, Seattle, Washington, USA
    Clin Pharmacol Ther 89:429-36. 2011
    ..We adapted a mathematical diabetes model to estimate NB and uncertainty of diabetes monotherapy...
  43. ncbi request reprint Ancillary risk information and pharmacogenetic tests: social and policy implications
    N B Henrikson
    Institute for Public Health Genetics, School of Public Health and Community Medicine, University of Washington, Seattle, WA 98195, USA
    Pharmacogenomics J 8:85-9. 2008
    ..Implications will vary with each test but tests should be evaluated individually within a framework that outlines the potential implications of ancillary information...
  44. ncbi request reprint The clinical and economic consequences of screening young men for genital chlamydial infection
    Rachel H S Ginocchio
    Department of Health Services, Maternal and Child Health, University of Washington, Seattle, Washington 98104, USA
    Sex Transm Dis 30:99-106. 2003
    ..Wide-scale application of urine-based screening of asymptomatic men for chlamydial infection has not been thoroughly assessed...
  45. doi request reprint Cost-consequences of ultrafiltration for acute heart failure: a decision model analysis
    Steven M Bradley
    Health Services Research and Development, VA Puget Sound Health Care System, Seattle, WA 98101, USA
    Circ Cardiovasc Qual Outcomes 2:566-73. 2009
    ..Ultrafiltration for heart failure may reduce costs associated with acute heart failure by decreasing rehospitalization rates compared to intravenous diuretics...
  46. ncbi request reprint Vascular catheter site care: the clinical and economic benefits of chlorhexidine gluconate compared with povidone iodine
    Nathorn Chaiyakunapruk
    Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA 98195 7630, USA
    Clin Infect Dis 37:764-71. 2003
    ..Use of chlorhexidine gluconate in place of the current standard solution for vascular catheter site care is a simple and cost-effective method of improving patient safety in the hospital setting...
  47. ncbi request reprint A review of selected patient-generated outcome measures and their application in clinical trials
    Kavita K Patel
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA 98195 7630, USA
    Value Health 6:595-603. 2003
    ..Nevertheless, application of these measures may be challenging, particularly in a clinical trial setting...
  48. ncbi request reprint An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients
    Lisa M Meckley
    University of Washington, Department of Pharmacy, Seattle, WA 98195, USA
    Thromb Haemost 100:229-39. 2008
    ..This difference may be due, in part, to pharmacokinetics factors (e.g. drug half-life), which are influenced primarily by CYP2C9; these findings should be confirmed in additional studies...
  49. ncbi request reprint Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose
    Mark J Rieder
    Department of Genome Sciences, University of Washington, Seattle, USA
    N Engl J Med 352:2285-93. 2005
    ..The management of warfarin therapy is complicated by a wide variation among patients in drug response. Variants in the gene encoding vitamin K epoxide reductase complex 1 (VKORC1) may affect the response to warfarin...
  50. ncbi request reprint Global epidemiology of hepatitis B virus
    Brian Custer
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, USA
    J Clin Gastroenterol 38:S158-68. 2004
    ..Preventing the most severe HBV disease consequences in infected individuals, such as cirrhosis and hepatocellular carcinoma, will require appropriate therapeutic agents...
  51. ncbi request reprint A cost-effectiveness analysis of intraoperative cholangiography in the prevention of bile duct injury during laparoscopic cholecystectomy
    David R Flum
    Robert Wood Johnson Clinical Scholars Program, Department of Surgery, University of Washington, Seattle, WA 98195 7183, USA
    J Am Coll Surg 196:385-93. 2003
    ..The cost implications of a management strategy involving routine IOC use have not been adequately evaluated...
  52. ncbi request reprint Using maximal sterile barriers to prevent central venous catheter-related infection: a systematic evidence-based review
    Kent K Hu
    Northwest Health Services Research and Development Program, Department of Medicine, University of Washington and VA Puget Sound HCS, 1660 South Columbian Way, HSR and D 152, Seattle, WA 98108, USA
    Am J Infect Control 32:142-6. 2004
    ..Accordingly, we conducted a systematic, evidence-based review of the medical literature to determine the value of maximal sterile barriers...
  53. ncbi request reprint The efficacy and safety of sibutramine for weight loss: a systematic review
    David E Arterburn
    Department of Veterans Affairs, Puget Sound Health Care System, Seattle, WA, USA
    Arch Intern Med 164:994-1003. 2004
    ..We conducted a systematic review to assess the efficacy and safety of sibutramine hydrochloride for weight loss...
  54. ncbi request reprint Health economic evaluation of non-melanoma skin cancer and actinic keratosis
    Mitchell K Higashi
    Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, Washington 98195, USA
    Pharmacoeconomics 22:83-94. 2004
    ....
  55. ncbi request reprint Toward evidence-based assessment for coverage and reimbursement of laboratory-based diagnostic and genetic tests
    Scott D Ramsey
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Am J Manag Care 12:197-202. 2006
    ....
  56. ncbi request reprint Economic analyses of human genetics services: a systematic review
    Josh J Carlson
    Cancer Prevention Program, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Genet Med 7:519-23. 2005
    ..The study's purpose was to conduct a structured review of economic analyses of genetic services. These will be increasingly valuable tools for assessing the clinical and economic outcomes of new medical technologies...
  57. pmc A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose
    Gregory M Cooper
    Department of Genome Sciences, University of Washington, Seattle, WA98195, USA
    Blood 112:1022-7. 2008
    ..Randomized clinical trials that account for these 2 genes should therefore produce results that are definitive and broadly applicable...
  58. ncbi request reprint Genetic testing and pharmacogenomics: issues for determining the impact to healthcare delivery and costs
    Kathryn A Phillips
    Program in Pharmacogenomics and Population Screening, School of Pharmacy, Institute for Health Policy Studies, and UCSF Comprehensive Cancer Center, University of California, San Francisco, 94143, USA
    Am J Manag Care 10:425-32. 2004
    ..To determine the potential impact of genetic testing and pharmacogenomics on healthcare delivery and costs...
  59. ncbi request reprint Cost of chronic hepatitis B infection in the United States
    Todd A Lee
    Midwest Center for Health Services and Policy Research, Hines VA Hospital, Hines, IL, USA
    J Clin Gastroenterol 38:S144-7. 2004
    ..To estimate the direct medical costs associated with chronic hepatitis B (CHB) infection in the United States...
  60. ncbi request reprint The cost of adjuvant chemotherapy in patients with early-stage breast carcinoma
    Nina Oestreicher
    Division of Research, Kaiser Permanente, Oakland, California 94612, USA
    Cancer 104:2054-62. 2005
    ..The objective of the current study was to evaluate the direct medical cost of adjuvant chemotherapy in women with early-stage breast carcinoma...
  61. ncbi request reprint Lipid-lowering drug use and cardiovascular events after myocardial infarction
    Olaf H Klungel
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Sorbonnelaan 16, 3584 CA Utrecht, The Netherlands
    Ann Pharmacother 36:751-7. 2002
    ....
  62. ncbi request reprint Chlorhexidine compared with povidone-iodine solution for vascular catheter-site care: a meta-analysis
    Nathorn Chaiyakunapruk
    Department of Pharmacy Practice, School of Pharmacy, Naresuan University, Pitsanuloak 65000, Thailand
    Ann Intern Med 136:792-801. 2002
    ..This study evaluated the efficacy of skin disinfection with chlorhexidine gluconate compared with povidone-iodine solution in preventing catheter-related bloodstream infection...
  63. ncbi request reprint Pharmacoeconomic evaluation of testing for angiotensin-converting enzyme genotype before starting beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitor therapy in men
    Anke Hilse Maitland-van der Zee
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht University Utrecht, The Netherlands
    Pharmacogenetics 14:53-60. 2004
    ..If other studies confirm that men with the DD genotype do not benefit from treatment with statins, screening for ACE genotype in men most likely will be a cost-effective strategy before initiating statin therapy...
  64. ncbi request reprint Bringing genomics to the bedside: a cost-effective pharmacogenomic test?
    David L Veenstra
    School of Pharmacy, University of California, San Francisco, California 94143, USA
    Pharmacogenetics 14:333-4. 2004
  65. ncbi request reprint Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population
    David L Veenstra
    School of Pharmacy, The Chinese University of Hong Kong, Hong Kong
    Pharmacogenet Genomics 15:687-91. 2005
    ..To evaluate the association of VKORC1 genetic variants with warfarin dose requirements in a Hong Kong Chinese patient population...